To Evaluate Safety & Immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 for COVID-19 in Healthy Adults Received 2 Doses of BNT162b2

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-02-08

Study Completion Date

2024-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate the safety and immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 as booster vaccine for COVID-19 in healthy adults who have received 2 doses of BNT162b2

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19

NCT04809389

Covid19

UNKNOWN PHASE1

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population

NCT04649021

SARS-CoV-2

COMPLETED PHASE2

Immunogenicity and Safety of COVID-19 Vaccine as a Booster Vaccination in Population Aged 18 Years and Above

NCT05664932

COVID-19

UNKNOWN PHASE3

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects

NCT04523571

SARS-CoV-2

COMPLETED PHASE1

Recombinant SARS-CoV-2 Fusion Protein Vaccine Booster Immunization Study to Evaluate the Safety and Immunogencity

NCT05239832

COVID-19 Pandemic

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized, double-blinded, placebo-controlled study to evaluate the safety and immunogenicity of DelNS1-2019-nCoV-RBD-OPT1 as booster vaccine for COVID-19 in healthy adults who have received 2 doses of BNT162b2. Each subject will receive 2 vaccinations or matching placebo 3 weeks apart.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Test Product

DelNS1-2019-nCoV-RBD-OPT1 virus titre at not less than 6.3 lg CCID50/dose, 2 doses 3 weeks apart, intranasal administration

Group Type EXPERIMENTAL

DelNS1-2019-nCoV-RBD-OPT1

Intervention Type BIOLOGICAL

Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray

Reference Product

Matching placebo, 2 doses 3 weeks apart, intranasal administration

Group Type PLACEBO_COMPARATOR

Matching placebo

Intervention Type BIOLOGICAL

Solution for Intranasal Spray

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DelNS1-2019-nCoV-RBD-OPT1

Influenza Virus Vector COVID-19 Vaccine for Intranasal Spray

Intervention Type BIOLOGICAL

Matching placebo

Solution for Intranasal Spray

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Informed Consent: The subject (or the subject's legally acceptable representative, if applicable) must be capable of giving written informed consent and, prior to the commencement of any study-specific procedure, must sign an ICF indicating the consent on the subject's voluntary participation in the study and compliance with the requirements and restrictions listed on the ICF.
2. BNT162b2 Vaccination Status: The subject must have received 2 doses of BNT162b2 in Hong Kong, with the second dose completed at least 180 days prior to the first vaccination.
3. Gender and Age: Male or female, at the age of ≥ 18 and ≤ 75 on the day of signing the ICF.
4. Body Weight and BMI: Body weight ≥ 45 kg and BMI ≥ 18.5 kg/m2 and \< 25 kg/m2 at screening and baseline.
5. Medical Conditions or Diagnoses: Existence of all of the following medical conditions or diagnoses:

1. Generally in good health with no clinically significant abnormality, as determined by medical history, physical examination, 12-lead ECG and clinical laboratory tests at screening and baseline;
2. Normal vital signs at screening and baseline, as defined by:

* Body (tympanic) temperature ≤ 37.5 oC;
* Resting pulse rate ≥ 50 and ≤ 100 bpm; and
* DBP ≥ 50 and ≤ 90 mmHg and SBP ≥ 90 and ≤ 140 mmHg.
6. Contraception: Willingness and agreement to undertake measures to avoid pregnancy of the subject or the subject's sexual partner(s) as detailed below:

1. A female subject who is a woman of childbearing potential (WOCBP) must be willing and agree to remain abstinent or practise at least one effective contraceptive method from at least 30 days prior to the first vaccination until 60 days after the second vaccination;
2. A male subject (i) who is sexually active with a WOCBP (except who is permanently sterile by bilateral orchiectomy or vasectomy) must be willing and agree to remain abstinent or practise at least one effective contraceptive method from the first vaccination until 60 days after the second vaccination; and (ii) must be willing and agree to refrain from sperm donation during the aforesaid period.
7. Breastfeeding: A female subject must be willing and agree to avoid engagement in breastfeeding at any time from the first vaccination until 60 days after the second vaccination.
8. Blood Donation: Willingness and agreement to avoid blood donation from screening to the end of the period of participation in this study.

Exclusion Criteria

1. Medical History: History of any of the following diseases or conditions:

1. COVID-19;
2. SARS;
3. Any significant respiratory diseases (e.g. COPD, asthma);
4. Any significant cardiovascular disease (e.g. angina, cardiac arrhythmias);
5. Blood dyscrasias or any significant disorder of coagulation;
6. Any chronic liver disease (e.g. autoimmune hepatitis and cirrhosis);
7. Any chronic infection (e.g. hepatitis B, hepatitis C and HIV);
8. Any malignant neoplastic disease;
9. Encephalopathy, neuropathy or unstable central nervous system (CNS) pathology;
10. Any psychiatric disorder, psychotic disorder, major affective disorder or suicidal ideation;
11. Any immunodeficiency or autoimmune disease;
12. Any severe allergic reaction (e.g. anaphylaxis) to any vaccine or substance, which requires hospitalization or emergency medical care;
13. Any nasal septal defect, cleft palate, nasal polyps or other nasal abnormality that might affect vaccine administration;
14. History of alcohol or illicit drug abuse, or used any illicit drug within 6 months prior to screening.
2. Medical Conditions or Diagnoses: Existence of any of the following medical conditions or diagnoses:

1. Positive serum pregnancy test at screening or positive urine pregnancy test at baseline (for WOCBP);
2. IgE level \> 1,000 IU/ml at screening;
3. Positive SARS-CoV-2 test result in deep throat saliva (DTS) within 4 days prior to the first vaccination;
4. Positive HIV test result at screening;
5. Positive HBsAg test result at screening;
6. Positive HCV antibody test result at screening;
7. Positive urine drug screen test result or positive blood alcohol test result at screening or baseline;
8. Clinically significant abnormality of T3, T4 or TSH at screening;
9. Clinically significant abnormality of PT (INR) or aPTT at screening.
3. Prior/Concomitant Interventions: Use of or undergoing any of the following prior or concomitant medications, therapies or interventions:

1. Any COVID-19 or coronavirus vaccine at any time prior to the first vaccination, except BNT162b2 or planned use of any such vaccine throughout the study;
2. Any vaccine other than COVID-19 or coronavirus vaccines within 28 days prior to the first vaccination, or planned use of any such vaccine up to 28 days after the second vaccination;
3. Any immune-modifying medication/therapy (e.g. immunomodulator and immunosuppressant) within 6 months prior to the first vaccination, or planned use of any such medication/therapy throughout the study;
4. Any blood product (including blood transfusion) or immunoglobulin within 3 months prior to the first vaccination, or planned use of any such therapy throughout the study;
5. Any anticoagulation medication within 28 days prior to the first vaccination, or planned use of any such medication up to 28 days after the second vaccination;
6. Any psychotropic medication within 28 days prior to the first vaccination, or planned use of any such medication up to 28 days after the second vaccination;
7. Regular use of any inhaled/nebulized corticosteroid;
8. Any intranasal preparation within 48 hours prior to the first vaccination, or planned use of any such preparation up to 48 hours after the second vaccination;
9. Any influenza antiviral medication within 48 hours prior to the first vaccination, or planned use of any such medication up to 14 days after the second vaccination;
10. Any prescription or over-the-counter medication within 7 days prior to the first vaccination, unless with the investigator's approval;
11. Donated ≥ 450 ml of blood within 28 days prior to the first vaccination;
12. Prior nasal surgery or nasal cauterization.
4. Prior/Concurrent Clinical Study: Prior or concurrent participation in any other clinical study, including:

1. Prior or current participation in another COVID-19 vaccine study;
2. Prior participation in any interventional clinical study and use of any investigational intervention within 90 days prior to the first vaccination;
3. Concurrent participation or plan for participation in another interventional clinical study during participation in this study.
5. Other Significant Medical Conditions: Any clinically significant concomitant disease or condition that, in the reasonable opinion of the investigator, may interfere with the subject's participation in this study or pose an unacceptable safety risk for the subject's participation in this study.
6. Special Conditions: Existence of any of the following special conditions:

1. Close contact with anyone known to have COVID-19 within 30 days prior to the first vaccination;
2. Travelled outside Hong Kong within 14 days prior to the first vaccination;
3. Planned to travel outside Hong Kong at any time during the period from screening to Day 50(±3) visit.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes